Testing effectiveness (Phase 2)Ended earlyNCT00947167
What this trial is testing
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Who this might be right for
Neuroendocrine TumorsCarcinoid TumorsAdrenal Gland Tumors+3 more
Pamela L. Kunz 4